News

The novel system converts light into electrical signals to stimulate retinal cells.

A shift toward minimally invasive, evidence-based interventions is redefining standards of care.

Sahar Bedrood, MD, PhD; Inder Paul Singh, MD; and AnnMarie Hipsley, DPT, PhD, recount moments that blended professional milestones with mentorship and legacy.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

An overview of the top 10 stories from Optometry Times in 2025.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, and psychological support in ophthalmic care.

Strategies for treatment intervals, drug selection, and patient expectations.

From artificial intelligence to home monitoring, Joel Schuman, MD, of Wills Eye Hospital, explores the innovations that could change how clinicians detect and treat glaucoma in the new year.

The value of attending industry meetings at the beginning of a career in ophthalmology.

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care.

As artificial intelligence tools become more common in research, students must navigate issues including plagiarism, data consent, and equitable application.

Panel examines drug mechanisms, patient factors, and strategies to optimize results.

Real-world insights guide the way to tailored treatment.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

Alternative management may avoid current concerns found with antibiotics.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

This approach helps distinguish diseases associated with macular atrophy.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Insights for diagnosing and managing these visible changes across specialties.

Explore the evolving challenges and insights in long-term follow-up for pediatric gene therapy, focusing on data integrity, ethical considerations, and patient retention.